Nanotechnology for the treatment of allergic conjunctival diseases

Allergic conjunctivitis is one of the most common external eye diseases and the prevalence has been increasing. The mainstay of treatment is topical eye drops. However, low bioavailability, low ocular drug penetration, transient resident time on the ocular surface due to tear turnover, frequent topi...

Full description

Saved in:
Bibliographic Details
Main Authors: Liu, Yu-Chi, Lin, Molly Tzu-Yu, Ng, Anthony Herr Cheun, Wong, Tina T., Mehta, Jodhbir Singh
Other Authors: School of Materials Science and Engineering
Format: Article
Language:English
Published: 2021
Subjects:
Online Access:https://hdl.handle.net/10356/146146
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Nanyang Technological University
Language: English
id sg-ntu-dr.10356-146146
record_format dspace
spelling sg-ntu-dr.10356-1461462023-07-14T15:46:49Z Nanotechnology for the treatment of allergic conjunctival diseases Liu, Yu-Chi Lin, Molly Tzu-Yu Ng, Anthony Herr Cheun Wong, Tina T. Mehta, Jodhbir Singh School of Materials Science and Engineering Science::Medicine Allergic Eye Diseases Nanomedicine Allergic conjunctivitis is one of the most common external eye diseases and the prevalence has been increasing. The mainstay of treatment is topical eye drops. However, low bioavailability, low ocular drug penetration, transient resident time on the ocular surface due to tear turnover, frequent topical applications and dependence on patient compliance, are the main drawbacks associated with topical administration. Nanotechnology-based medicine has emerged to circumvent these limitations, by encapsulating the drugs and preventing them from degradation and therefore providing sustained and controlled release. Using a nanotechnology-based approach to load the drug is particularly useful for the delivery of hydrophobic drugs such as immunomodulatory agents, which are commonly used in allergic conjunctival diseases. In this review, different nanotechnology-based drug delivery systems, including nanoemulsions, liposomes, nanomicelles, nanosuspension, polymeric and lipid nanoparticles, and their potential ophthalmic applications, as well as advantages and disadvantages, are discussed. We also summarize the results of present studies on the loading of immunomodulators or nonsteroidal anti-inflammatory drugs to nano-scaled drug delivery systems. For future potential clinical use, research should focus on the optimization of drug delivery designs that provide adequate and effective doses with safe and satisfactory pharmacokinetic and pharmaco-toxic profiles. Published version 2021-01-28T03:43:33Z 2021-01-28T03:43:33Z 2020 Journal Article Liu, Y.-C., Lin, M. T.-Y., Ng, A. H. C., Wong, T. T., & Mehta, J. S. (2020). Nanotechnology for the Treatment of Allergic Conjunctival Diseases. Pharmaceuticals, 13(11), 351-. doi:10.3390/ph13110351 1424-8247 https://hdl.handle.net/10356/146146 10.3390/ph13110351 33138064 2-s2.0-85094622641 11 13 en Pharmaceuticals © 2020 The Authors. Licensee MDPI, Basel, Switzerland. This article is an open accessarticle distributed under the terms and conditions of the Creative Commons Attribution(CC BY) license (http://creativecommons.org/licenses/by/4.0/). application/pdf
institution Nanyang Technological University
building NTU Library
continent Asia
country Singapore
Singapore
content_provider NTU Library
collection DR-NTU
language English
topic Science::Medicine
Allergic Eye Diseases
Nanomedicine
spellingShingle Science::Medicine
Allergic Eye Diseases
Nanomedicine
Liu, Yu-Chi
Lin, Molly Tzu-Yu
Ng, Anthony Herr Cheun
Wong, Tina T.
Mehta, Jodhbir Singh
Nanotechnology for the treatment of allergic conjunctival diseases
description Allergic conjunctivitis is one of the most common external eye diseases and the prevalence has been increasing. The mainstay of treatment is topical eye drops. However, low bioavailability, low ocular drug penetration, transient resident time on the ocular surface due to tear turnover, frequent topical applications and dependence on patient compliance, are the main drawbacks associated with topical administration. Nanotechnology-based medicine has emerged to circumvent these limitations, by encapsulating the drugs and preventing them from degradation and therefore providing sustained and controlled release. Using a nanotechnology-based approach to load the drug is particularly useful for the delivery of hydrophobic drugs such as immunomodulatory agents, which are commonly used in allergic conjunctival diseases. In this review, different nanotechnology-based drug delivery systems, including nanoemulsions, liposomes, nanomicelles, nanosuspension, polymeric and lipid nanoparticles, and their potential ophthalmic applications, as well as advantages and disadvantages, are discussed. We also summarize the results of present studies on the loading of immunomodulators or nonsteroidal anti-inflammatory drugs to nano-scaled drug delivery systems. For future potential clinical use, research should focus on the optimization of drug delivery designs that provide adequate and effective doses with safe and satisfactory pharmacokinetic and pharmaco-toxic profiles.
author2 School of Materials Science and Engineering
author_facet School of Materials Science and Engineering
Liu, Yu-Chi
Lin, Molly Tzu-Yu
Ng, Anthony Herr Cheun
Wong, Tina T.
Mehta, Jodhbir Singh
format Article
author Liu, Yu-Chi
Lin, Molly Tzu-Yu
Ng, Anthony Herr Cheun
Wong, Tina T.
Mehta, Jodhbir Singh
author_sort Liu, Yu-Chi
title Nanotechnology for the treatment of allergic conjunctival diseases
title_short Nanotechnology for the treatment of allergic conjunctival diseases
title_full Nanotechnology for the treatment of allergic conjunctival diseases
title_fullStr Nanotechnology for the treatment of allergic conjunctival diseases
title_full_unstemmed Nanotechnology for the treatment of allergic conjunctival diseases
title_sort nanotechnology for the treatment of allergic conjunctival diseases
publishDate 2021
url https://hdl.handle.net/10356/146146
_version_ 1772826934778003456